Bristol-Myers Squibb Co news

   Watch this stock
Showing stories 1 - 10 of about 155   

Articles published

BMY 60.27 -0.87 (-1.42%)
price chart
Bristol-Myers Squibb Co (BMY) HIV-1 Combo Drug Gets FDA Nod
Bristol-Myers Squibb Co (NYSE:BMY) announced Thursday that the US Food and Drug Administration (FDA) has approved its drug Evotaz as a fixed-dose combination of atazanavir, cobicistat, and other antiretroviral agents to treat adult patients with human ...
US Food and Drug Administration Approves Bristol-Myers Squibb's Evotaz ...  Business Wire (press release)
Bristol-Myers Squibb (BMY) Confirms FDA Approval of Evotaz to Treat HIV
Company News: Bristol-Myers Squibb Co (NYSE:BMY)
Celldex Therapeutics (CLDX) and Bristol-Myers Squibb Co (NYSE:BMY) announced the initiation of a Phase 1/2 dose escalation and cohort expansion study examining the investigational combination of varlilumab, Celldex's CD27 targeting investigational ...
Celldex Therapeutics and Bristol Myers-Squibb Announce Initiation of Phase 1 ...  CNNMoney
Technical Commentary on Pharma Stocks -- Merck, AbbVie, Bristol-Myers ...
Bristol-Myers Squibb Co.'s stock finished Thursday's session 0.31% lower at $61.14. A total of 6.39 million shares were traded, which was below its three months average volume of 6.83 million shares.
Bristol-Myers Squibb Co (NYSE:BMY) still close to 52-week high post Q4 earnings
Bristol-Myers Squibb Co (NYSE:BMY) (TREND ANALYSIS) reported Q4-14 earnings figures on January 27th. The company announced actual earnings per share of $0.46 against the consensus Street estimate of $0.41, beating estimates by $0.05.
Bristol-Myers 2015 Sales Forecast Hit by Dollar's Strength  Businessweek
Bristol-Myers beats Street 4Q forecasts
Bristol-Myers Squibb Co (BMY) Releases FY15 Earnings Guidance
Bristol-Myers Squibb logo Bristol-Myers Squibb Co (NYSE:BMY) issued an update on its FY15 earnings guidance on Tuesday morning.
Barclays Rating Disclosure on Bristol-Myers Squibb Co  Stafford Daily
Closing Bell Reports: MannKind Corp. (MNKD), Lowe's Companies Inc. (LOW ...  WallStreet Scope
Options Check-Up: Bristol-Myers Squibb, Merck & Co., and Novartis AG
Among the stocks attracting attention from options traders lately are pharmaceutical firms Bristol-Myers Squibb Co (NYSE:BMY), Merck & Co.
Bristol-Myers Squibb Co (NYSE:BMY) Price Target Raised at SunTrust  Realist Investor
Bristol-Myers Squibb Earnings Preview: Increasing Sales From New Drugs May ...  Trefis
Bristol-Myers Squibb Co (NYSE:BMY) Misses Estimates, Stock Rallies
Bristol-Myers Squibb Co (NYSE:BMY) was one of the notable decliners in the trading session today. The stock plunged by close to 2 percent on the back of above average volumes which is seen as a bearish sign.
Bristol-Myers Squibb CEO steps down, replaced by COO
The succession plan is familiar to Bristol-Myers Squibb BMY , and smoother than some of its past leadership changes. The outgoing chairman, James Cornelius, also previously served as the company's CEO, taking on the job after his predecessor, Peter ...
Bristol-Myers Squibb Appoints Giovanni Caforio, MD, Chief Executive Officer ...  MarketWatch
Bristol-Myers Squibb Co.'s(NYSE:BMY) new cancer drug, a hit or not?
It seems that Bristol-Myers Squibb Co (NYSE:BMY) has made a good decision to invest heavily in the immuno-oncology sector since it's paying off for the company.
Bristol-Myers Squibb jumps on Opdivo cancer drug test  MarketWatch
Bristol-Myers Squibb Co (NYSE:BMY) near its 52-week high with important volume  Markets Wired
Bristol-Myers Squibb Co. (BMY) Price Target Raised to $59 at Deutsche Bank
Deutsche Bank maintained a Hold rating on Bristol-Myers Squibb Co. (NYSE: BMY) and raised its price target to $59.00 (from $52.00).